Table 2.
Summary of clinical trials with MSC for liver failure.
| Trial PI | Number of patients | Cell type | Cell number | Administration route | Disease |
|---|---|---|---|---|---|
| Kharaziha et al. [46] | 8 | BM-MSCs | 3 × 107 to 5 × 107 | Portal vein | Chronic liver failure |
| Amer et al. [83] | 40 | BM-MSCs | 2 × 107 cells | Intrasplenic vs. intrahepatic | End-stage liver failure |
| Kantarcıoğlu et al. [88] | 12 | BM-MSCs | 1 × 106 cells/kg | Peripheral vein | Liver cirrhosis |
| Suk et al. [89] | 55 | BM-MSCs | 5 × 107 | Hepatic artery | Liver cirrhosis |
| El-Ansary et al. [90] | 12 | BM-MSCs | 1 × 106 cells | Intrasplenic vs. peripheral vein | Chronic liver failure |
| Peng et al. [91] | 23 | BM-MSCs | 1 × 107 cells | Hepatic artery | Liver failure |
| Mohamadnejad et al. [92] | 25 | BM-MSCs | 1.95 × 108 cells | Peripheral vein | Decompensated liver cirrhosis |
| Zhang et al. [93] | 46 | UC-MSCs | 0.5 × 106/kg | Peripheral vein | Decompensated liver cirrhosis |
| Yu et al. [94] | 35 | BM-MSCs | 5 × 106 cells | Peripheral vein | End-stage liver failure |
| Zhang et al. [95] | 30 | UC-MSCs | ≥2 × 107 cells | Hepatic artery | Decompensated liver cirrhosis |
| Liu et al. [96] | 35 | UC-MSCs | >5 × 107 cells | Peripheral vein vs. hepatic artery | Acute-on-chronic liver failure |
| Sakai et al. [97] | 4 | AD-MSCs | 3.3 × 105 to 6.6 × 105 cells/kg | Hepatic artery | Liver cirrhosis |